Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 16, 2020 - Issue
Submit an article Journal homepage
141
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial

Runhui Wu1 Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Children's Health Center, Beijing, People’s Republic of ChinaView further author information
,
Jing Sun2 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-5130-4835View further author information
ORCID Icon,
Weiqun Xu3 Department of Hematology and Oncology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, People’s Republic of ChinaView further author information
,
Qun Hu4 Department of Pediatric Hematology, Tongji Hospital, Tongji Medical College of HUST, Wuhan, People’s Republic of ChinaView further author information
,
Wenqian Li5 Department of Hematology and Rheumatology, Qinghai Provincial People’s Hospital, Xining, People’s Republic of ChinaView further author information
,
Jianwen Xiao6 Department of Hematology, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-8322-9286View further author information
ORCID Icon,
Feng’e Yang7 Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-6357-750XView further author information
ORCID Icon,
Xiaojing Zeng8 Department of Blood Transfusion, The Affiliated Hospital of Guizhou Medical University, Guiyang, People’s Republic of ChinaView further author information
,
Yun Zeng9 Department of Hematology, First Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of ChinaView further author information
,
Jianfeng Zhou4 Department of Pediatric Hematology, Tongji Hospital, Tongji Medical College of HUST, Wuhan, People’s Republic of ChinaView further author information
,
Irina Matytsina10 Biopharm Medical & Science, Novo Nordisk A/S, Søborg, DenmarkView further author information
,
Sali Zhang11 Biopharm Clinical, Medical and Regulatory Affairs, Novo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, People’s Republic of ChinaView further author information
,
Michael Pluta12 Statistical Consultancy, Quanticate Ltd, Hitchin, UKView further author information
&
Renchi Yang13 Thrombosis and Haemostasis Centre, State Key Laboratory of Experimental Hematology, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 567-578 | Published online: 23 Jun 2020

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (2)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.